Kemmler W, et al. - In the Franconian Sarcopenic Obesity (FranSO) trial, changes in obesity parameters and cardiometabolic risk were assessed in men with sarcopenic obesity (SO) who were randomly assigned to whey protein supplementation (WPS), whole-body electromyostimulation (WB-EMS) and protein supplementation [(WB-EMS&P)], or non-intervention control (CG). After 16 weeks of intervention, total body fat mass (TBF) was shown to be significantly reduced in the WPS and WB-EMS&P groups, but not in the CG. It was suggested that in order to address obesity and cardiometabolic risk in older community-dwelling men with SO unable or unmotivated to exercise conventionally, it may be feasible to opt for moderate-to-high dose whey protein supplementation, especially in combination with WB-EMS.